Shares of pharmaceutical major Cipla dropped over 4 per cent on Wednesday at ₹1,417 per share after analysts highlighted near-term challenges following a muted performance in the second quarter results for the current financial year (Q2FY25).
In Q2FY25, Cipla's domestic business underperformed due to seasonal weakness in the anti-infective and trade generics business. However, this was offset by strong growth in Africa, emerging markets, and European business, said analysts. Growth for Cipla was lower in the US and India than analyst estimates.
"The narrative for Cipla has worsened in the recent past, driven by US prospects and a slowdown in India. Supply constraints in Acromegaly drug Lanreotide, potential competition for the drug in due course, a delay in clearance of the Goa site resulting in Cipla failing to have the first-mover advantage (a competitor has gained approval) present potential risks to earnings," analysts at Nomura said in a report.
Esta historia es de la edición October 31, 2024 de Business Standard.
Comience su prueba gratuita de Magzter GOLD de 7 días para acceder a miles de historias premium seleccionadas y a más de 9,000 revistas y periódicos.
Ya eres suscriptor ? Conectar
Esta historia es de la edición October 31, 2024 de Business Standard.
Comience su prueba gratuita de Magzter GOLD de 7 días para acceder a miles de historias premium seleccionadas y a más de 9,000 revistas y periódicos.
Ya eres suscriptor? Conectar
IndiGo stock takes off on rating upgrade
Elara Capital gives 'buy' rating after IndiGo's highest-ever traffic in November
Wait for NAV, price on exchange to converge before investing
Indian investors seeking to diversify their portfolios through overseas exchange-traded funds (ETFs) are paying a premium.
Multiple triggers for Vedanta stock
Vedanta’s stock is experiencing multiple positive triggers, primarily driven by favorable aluminium and zinc price trends. The company's demerger plans, while modified, are expected to unlock value and improve capital allocation. Key projects coming online in the next 12-18 months, including alumina refinery expansion and captive mines, are poised to significantly boost earnings.
Markets settle flat in muted trade
Benchmark indices Sensex and Nifty ended flat in listless trading on Thursday amid a lack of near-term triggers and unabated foreign fund outflows.
India Third-Best Performing Major Market in 2024
The domestic market capitalization has soared 18.4 percent to $5.18 trillion in 2024, adding $806 billion.
MP High Court stays Burmans' Religare open offer
In a strange turn of events, the Madhya Pradesh High Court's Jabalpur Bench has stayed the Burman family's open offer to acquire an additional 26 per cent stake in Religare Enterprises, and the company's annual general body meeting.
IPO Mopup Likely to Top ₹2 Trillion Mark Next Year
Fund mobilisation through initial public offerings (IPOs) will continue to rise in 2025 and the total amount is expected to breach the ₹2 trillion mark, investment banking firm Pantomath Group estimates.
Derivatives volume drops 37%
Stricter trading norms help cool off speculative activity in December so far
Indian crypto investors ride Bitcoin, altcoin wave
The majority of crypto investors in the country have invested in mainstream virtual digital assets (VDAs) such as Bitcoins, altcoins like Dogecoin, Shiba Inu, and Ethereum, followed by non-fungible tokens (NFTs) and stablecoins, a compilation of year-end reports of crypto majors CoinDCX and CoinSwitch revealed.
28% OF LS SEATS HAD NO WOMAN CANDIDATE IN 2024
The Election Commission of India on Thursday released 42 statistical reports for the Lok Sabha (LS) elections 2024.
